Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
80.5M
-
Number of holders
-
40
-
Total 13F shares, excl. options
-
56.8M
-
Shares change
-
+56.8M
-
Total reported value, excl. options
-
$658M
-
Value change
-
+$658M
-
Number of buys
-
40
-
Price
-
$11.58
Significant Holders of BridgeBio Oncology Therapeutics, Inc. - COMMON STOCK (BBOT) as of Q3 2025
40 filings reported holding BBOT - BridgeBio Oncology Therapeutics, Inc. - COMMON STOCK as of Q3 2025.
BridgeBio Oncology Therapeutics, Inc. - COMMON STOCK (BBOT) has 40 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 56.8M shares
of 80.5M outstanding shares and own 70.61% of the company stock.
Largest 10 shareholders include Cormorant Asset Management, LP (17.9M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (4.89M shares), Omega Fund Management, LLC (3.29M shares), WELLINGTON MANAGEMENT GROUP LLP (2.96M shares), EcoR1 Capital, LLC (2.82M shares), Alphabet Inc. (2.82M shares), ENAVATE SCIENCES GP, LLC (2.63M shares), CITADEL ADVISORS LLC (2.54M shares), BlackRock, Inc. (2.05M shares), and NOVO HOLDINGS A/S (1.96M shares).
This table shows the top 40 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.